Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
November 05, 2020 11:50 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is...
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
November 02, 2020 09:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn’s...
Rexahn and Ocuphire Enter into Definitive Merger Agreement
June 17, 2020 23:30 ET
|
Rexahn Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates $21.15 Million Investment Committed by...
Rexahn to Explore Strategic Alternatives
September 24, 2019 06:50 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) today announced that it has commenced a process to explore and evaluate strategic alternatives to...
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
August 07, 2019 06:30 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Announces Move to Nasdaq
May 28, 2019 16:10 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., May 28, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results
May 13, 2019 08:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
April 16, 2019 08:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md. and SUZHOU, China, April 16, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage, biopharmaceutical company focused on oncology, and BioSense...
Rexahn Effects 1-for-12 Reverse Stock Split
April 12, 2019 08:00 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, MD, April 12, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...
Rexahn Announces Reverse Stock Split
April 10, 2019 16:07 ET
|
Rexahn Pharmaceuticals, Inc.
ROCKVILLE, Md., April 10, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient...